Cohance Lifesciences announces $10 million investment in US-based arm

Cohance Lifesciences is investing USD 10 million to expand bioconjugation capabilities at its US subsidiary, NJ Bio, enhancing its ADC solutions. This investment aims to support innovators from early development through late-phase clinical supply. Additionally, Cohance is investing Rs 23 crore in a new oligonucleotide building block manufacturing facility in Hyderabad, part of a broader capacity expansion program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G6moSWY
via IFTTT